Minimally Invasive Brain Science: Revenue is expected to increase by about 34% to 37% year-on-year in the first half of the year

Minimally invasive neuroscience announced that its revenue in the first half of the year is expected to reach 400 million to 410 million yuan, a year-on-year increase of about 34% to 37%. The revenue growth is mainly attributed to breakthroughs in overseas business, with revenue expected to increase by about 70% to 90%; the market share of intracranial atherosclerotic stenosis products has increased; spring coil products have benefited from winning the bid for centralized procurement and accelerated the development of blank markets; and multiple acute ischemic stroke and pathway products have accelerated hospital access and clinical use.